Citicoline Triggers Proteome Remodeling and Proteostatic Adaptation: Evidence from Shotgun Proteomics.
Dario Cavaterra, Sara Giammaria, Irene Pandino...
https://pubmed.ncbi.nlm.nih.gov/41599168/Actively Recruiting
Led by Omikron Italia S.r.l. · Updated on 2024-03-12
1000
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are investigating the effects of citicoline eye drops 2% on reducing visual field loss in patients with progressing open-angle glaucoma OAG who are receiving standard clinical care. This study also aims to assess changes in eye structure using Spectral Domain Optical Coherence Tomography SD-OCT and evaluate the safety of citicoline eye drops. Open-angle glaucoma is a chronic disease where pressure inside the eye is a key factor, but some patients continue to worsen despite controlled pressure, so neuroprotective treatments like citicoline are being explored. Participants will be randomly assigned to receive either citicoline eye drops 2% or placebo eye drops, applied as one drop in the study eye three times daily for three years. All patients will continue with any intraocular pressure-lowering treatments needed, with study eye drops given at least 20 minutes after those medications. The trial is double-blind, meaning neither participants nor researchers know which treatment is given, ensuring unbiased results. During the study, patients will undergo regular assessments including visual field tests to measure vision loss progression, structural eye scans, and safety evaluations focusing on intraocular pressure. Researchers will track changes over three years to evaluate how the eye drops affect disease progression and safety. The trial includes careful monitoring to understand the potential benefits and risks of adding citicoline eye drops to standard glaucoma care.
CONDITIONS
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
C
Carla Russo
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Omikron Italia S.r.l.
Lead Sponsor
OPIS Spain
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 years
Participants use either Citicoline eye drops 2% or placebo eye drops in the study eye three times daily along with IOP-lowering medication for glaucoma control.
Regular visits throughout the 3-year treatment period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Dario Cavaterra, Sara Giammaria, Irene Pandino...
https://pubmed.ncbi.nlm.nih.gov/41599168/Omikron Italia S.r.l.
Lead Sponsor
OPIS Spain
Collaborating Sponsor